二甲双胍与肿瘤相关性的新观点与挑战  

New ideas and challenges on the correlation between metformin and tumor

作　　者：李璞[1] 乔虹[1] Li Pu;Qiao Hong(Department of Endocrinology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150086,China)

机构地区：[1]哈尔滨医科大学第二附属医院内分泌科

出　　处：《现代肿瘤医学》2020年第3期486-489,共4页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81673108,81872560)

摘　　要：2型糖尿病(T2DM)是一种慢性疾病,在全球范围内迅速增长,它是各类癌症的重要风险因素。而二甲双胍是治疗T2DM最常用的处方药。通过流行病学和临床研究表明,使用二甲双胍可以降低T2DM患者的癌症风险,改善癌症患者的预后和生存率。此外,二甲双胍在癌症治疗中的临床试验正在扩大到非糖尿病人群。越来越多的研究者认为二甲双胍将会成为癌症预防和治疗的一个有吸引力的候选药物。在这里,我们总结了近年来二甲双胍在肿瘤预防与治疗中的流行病学证据与相关研究进展、二甲双胍的抗肿瘤机制,并探讨了提高二甲双胍对肿瘤的敏感性和预防肿瘤转移的可能性。Type 2 diabetes mellitus(T2DM)is a chronic disease,and it is rapidly growing in worldwide and is an important risk factor for various types of cancer.Metformin is the most commonly prescribed drug for type 2 diabetes mellitus.Epidemiological and clinical observation studies have shown that metformin use reduces risk of cancer in patients with type 2 diabetes mellitus and improves prognosis and survival rate of the cancer patients.Furthermore,ongoing clinical trials of metformin in cancer therapy are extending to nondiabetic population.A growing number of researchers believe that metformin will become an attractive candidate for cancer prevention and treatment.This review summarizes recent epidemiological evidence and progress in studies of metformin use in cancer,mechanism of metformin's anticancer effect and discusses the possibility to enhance its sensitivity to tumors and to prevent cancer metastasis.

关 键 词：二甲双胍 糖尿病 癌症 肿瘤 化疗 防治 预后 

分 类 号：R730.5[医药卫生—肿瘤]